The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in a phase 2 trial. The mTOR pathway was activated i...

Full description

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Witzig, Thomas E., Reeder, Craig, Han, Jing Jing, LaPlant, Betsy, Stenson, Mary, Tun, Han W., Macon, William, Ansell, Stephen M., Habermann, Thomas M., Inwards, David J., Micallef, Ivana N., Johnston, Patrick B., Porrata, Luis F., Colgan, Joseph P., Markovic, Svetomir, Nowakowski, Grzegorz S., Gupta, Mamta
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2015
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504947/
https://ncbi.nlm.nih.gov/pubmed/25921059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-629543
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items